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RCCS Ethics Approvals
The RCCS was approved by the Uganda Virus Research Institute Research and Ethics Committee, the Uganda National Council for Science and Technology, and the Western Institutional Review Board (Olympia, WA).
History of the RCCS and study design
Communities for the Rakai Community Cohort Study originally were selected as part of a community-randomized trial on treatment of sexually transmitted infections for HIV prevention. The original selection criteria were location in south and central regions of Rakai district, yearround road access, population stability, and projected HIV incidence of up to 2.0/100pys. The decision on number and size of the communities were based on providing adequate power for the original trial. 1 After the trial, these communities continued to be followed, but under the auspices of an observational cohort study which continues to this day.
RCCS recruitment and follow-up
To identify eligible cohort participants, a household census enumerates all persons by gender, age, and duration of residence, regardless of whether they are present or currently absent. After the census, the RCCS surveys all present, age-eligible residents providing written informed consent. Two attempts are made to contact individuals who are censused and eligible but who do not participate in the surveys. In recent surveys, we performed mobile phone outreach to survey participants from prior rounds who were not present at subsequent surveys. There were no specific incentives for follow-up given to the HIV incidence cohort, but all participants were compensated for time and travel.
Combination HIV Prevention Scale-Up
Male circumcision. Prior to 2002, with the exception of Muslims (~12% of the male cohort), MC services in Rakai were very limited. From 2003 to 2006, RHSP conducted a large randomized controlled trial of MC which demonstrated significant efficacy for HIV prevention in men. 2 In 2007, the World Health Organization recommended that MC be part of CHP strategies, 3 and RHSP first provided MC services to trial controls and then free MC services throughout Rakai, with funding from the U.S. President's Emergency Plan for AIDS Relief (PEPFAR). PEPFAR support, RHSP provided ART to RCCS participants and non-RCCS clients through mobile and static clinics. 5 In 2013, services were provided by Ministry of Health (MOH) personnel with RHSP supervision and monitoring ("District Led Programming"). From 2004, the CD4 cell count criteria for ART initiation was <250 cells/mm3, subsequently raised to <350 cells/mm3 in 2011 and to <500 cells/mm3 in January 2014 along with ART provision to pregnant and breastfeeding women, serodiscordant couples, and key populations (e.g., commercial sex workers, truckers, and fisherfolk) regardless of CD4 count. HIV-positive individuals on ART were monitored clinically, with six monthly CD4+ cell count and viral load testing, the results of which were routinely provided to patients as part of adherence counseling. ART was also available through non-governmental organizations.
HIV testing services, condoms, and behavioral interventions. Free HIV testing services were provided to all RCCS participants. Condoms and behavioral counseling were also provided and HIV prevention messaging campaigns were implemented. 6 Intervention studies have also been conducted by RHSP to improve linkage and adherence to pre-ART and ART care, leading to the integration of peer supporters and "treatment buddies" into routine care. 5, 7, 8 
RCCS Laboratory Methods
All RCCS participants are offered free voluntary counseling and HIV testing. The vast majority (>90%) of participants over the lifetime of the cohort consent to be tested and to receive their results. A small percentage (<5%) agree to be tested but choose not to receive their HIV results. Since 2011, HIV rapid tests results are returned to participants immediately through on-site posttest counselors. Prior to rapid testing, a community-based counselor system was used to return results to participants.
As HIV testing methods evolved, RCCS testing algorithms have changed accordingly (see next section for more details). In brief, prior to October 2011, HIV testing used enzyme immunoassays (EIAs) with confirmation via Western Blot. Subsequently a field-validated parallel three test rapid HIV testing algorithm was introduced with demonstrated high sensitivity (>99.5%) and specificity (>99.5%). 9, 10 All rapid test positives are confirmed by two EIAs, with Western blot or PCR for discordant EIA results.
HIV viral loads were retrospectively measured for this analysis using stored sera for all HIVpositive participants in surveys 8 (Jul.2009) and 12 (Jan.2016). HIV-1 viral load testing was performed using the Abbott RealTime assay (Abbott Molecular, Inc., Des Plaines, IL 60018).
History of HIV Testing Algorithms in the RCCS
The RCCS HIV testing algorithm has changed over time. Details of testing methods are described below. 
1 st April 2009 (Serial EIA testing)
EIAs were run in series and participants who had already tested HIV seropositive twice were no longer tested.
Samples testing seronegative on Murex HIV 1.2. were reported as HIV-seronegative and no additional testing was performed.
Samples from persons testing HIV-seropositive for the first time with Murex 1.2 were also run with the Vironostika HIV Uni-form 11 plus O.
Concordant HIV seropositive results were reported as seropositive and discordant results were further evaluated on WB.
Indeterminate WB's were recorded as such (uncertain) and an RNA PCR (Roche Amplicor 1.5) was performed.
October 2011 (Field validation or rapid HIV tests with EIA)
Rapid HIV testing was introduced. Determine and Stat Pak rapid tests were run in parallel. In the case of rapid discordant results, samples were further tested on Unigold according to Ugandan National HIV guidelines.
In order to assess the validity of rapid test results (obtained in the community), all rapid seropositive samples, rapid discordant samples as well as weak positive rapid samples were run on two EIAs starting with Murex and then proceeding to Vironostika HIV Uni-form 11 plus O when the Murex test result was seropositive. If the sample was seronegative on Vironostika, the sample was further tested with BioRad (GS HIV-1/2 plus O (Bio Rad)). For those samples that were seropositive on BioRad, a WB or RNA PCR was also performed. The rapid test algorithm was adopted in lieu of serial EIA tests following the rapid test field validation (see above). All new seropositives were confirmed by two EIAs, with WB or RNA PCR for discordant EIAs.
January 2013
Tertiary EIA and WB testing was discontinued after systematic comparison retaining and excluding results. Two EIAs were used to confirm seropositive rapid results and to resolve rapid discordant results. If EIAs were discordant, WB or RNA PCR were performed.
December 2015-present
Murex was used for first-line confirmatory testing for all rapid HIV seropositive and discordant test results. BioRad was used for second-line confirmatory testing. References the seven RCCS survey periods (calendar time) during which HIV incidence was assessed. The reference period includes visit intervals prior to CHP scale-up which began with the sixth survey. Incidence is reported at the visit incidence cases were first detected. The period-specific mean incidence rates during the survey interval between present and prior survey were estimated.
Age (years)
Individual-level time-varying age was analyzed as a categorical variable (e.g., five-year age groups with exception of the oldest age group, 40-49 years). Age was recorded by interviewer using the participant verification form prior to the RCCS survey. Table 6 )
Construction of survey participation weights

Construction of censoring weights
Model IX: Sensitivity analysis with stabilized inverse probability weights (Supplemental Table 7 )
Survey/Calendar time (primary exposure variable)
References the seven RCCS survey periods (calendar time) during which HIV incidence was assessed. The reference period includes visit intervals prior to CHP scale-up which began with the sixth survey.
Incidence is reported at the visit cases were first detected but is in reference to the mean incidence during the survey period between present and prior survey.
Age (years) 
Supplemental statistical methods
All statistical analyses were conducted using the R statistical software (version 3.3.2).
Analysis of HIV incidence community ART coverage, community prevalence of viremia, and community MC coverage
Scale up of ART and male circumcision coverage as well as prevalence of viremia at the community-level was assessed over the study period. ART coverage in community i at visit j was estimated as the proportion of HIV positive persons in community i at time j who self-reported ART use. Male circumcision coverage was similarly defined using self-reported data from men. The prevalence of population viremia in an RCCS community at a given visit was calculated as follows:
We multiply ART coverage by 0.90 because ~90% of self-reported ART users were suppressed at the two time points we assessed population viremia and in a prior validation study of self-reported ART use. Given that there is underreporting of ART use in the RCCS, our estimates of community-level viremia are likely an upper bound.
Next, we assessed HIV incidence and individual HIV risk as a function of community-level ART coverage which was analyzed as a categorical variable (0-10% coverage, 10-20%, 20-30%, 40-50%, >50%). Similar analyses were also performed for MC coverage (0-10% coverage, 10-20%, 20-30%, 40-50%, >50%) and prevalence of viremia (0-7.5%,7.5-10%, 10-12.5%, 12.5%-15%, 15-17.5%, >17.5%). Analyses were performed for women, men and uncircumcised men where coverage of ART and viremia were measured in the opposite sex.
Estimation stabilized inverse probability weights methods
Inverse probability weighting was implemented using methods previously described by Cole et al. (see Cole S. and Hernan M.A. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008 Sep 15; 168 (6): 656-664 for more detail). Briefly, models for survey participation and censoring were specified separately. Each person-visit was treated as an observation in the models which included the timefixed and time-varying variables specified in the table above. Our model of survey participation included variables collected at time of census (age, gender and community of residence) whereas the censoring model included demographic and sexual behavioral variables collected at census and time of survey. The denominator of the weights was a logistic regression model for the probability of contributing person-time to the incidence cohort which was defined as the joint probability of participating in the survey and of being observed at the following survey. The numerator was the joint probability of the marginal distributions for participation and censoring. Weighted incidence rate ratios were estimated using Poisson regression assuming independence between individual participant observations conditional on observed covariates.
Supplemental Figure 1 . Map of Rakai region and 30 continuously surveyed RCCS study communities. Agrarian communities are shown as green triangles (n=23) and trading communities (n=7) as yellow circles. 
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Supplemental Figure 4 : Sexual behaviors among HIV-negative participants who were interviewed at the following survey and those who were not by calendar time. Condom use was assessed among those reporting casual/non-stable sexual partnerships only because condom use within marital unions is low. Table 3A . Probability of self-reported ART use by survey period and gender with and without inverse probability weights for survey participation. 
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Supplemental Table 4A . HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence among all participants in HIV incident cohort (Model I) at each visit interval during combination HIV prevention (CHP) scale-up compared to HIV incidence in the period prior to scale-up. .001 IRR=Incidence rate ratio, adjIRR=adjusted incidence rate ratio; *Stable partners include marital unions and long-term consensual partnerships; Casual partners include all other types partnerships. Condom use only assessed among individuals reporting non-stable partnerships because of very low levels (<5%) condom use within stable partnerships. Those reporting non-stable partners may also have had stable partners.
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Supplemental Table 4C . HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence among male participants in HIV incident cohort (Model III) at each visit interval during combination HIV prevention (CHP) scale-up compared to HIV incidence in the period prior to scale-up. .001 IRR=Incidence rate ratio, adjIRR=adjusted incidence rate ratio; *Stable partners include marital unions and long-term consensual partnerships; Casual partners include all other types partnerships. Condom use only assessed among individuals reporting non-stable partnerships because of very low levels (<5%) condom use within stable partnerships. Those reporting non-stable partners may also have had stable partners.
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Supplemental Table 4D . HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence among uncircumcised male participants in HIV incident cohort (Model IV) at each visit interval during combination HIV prevention (CHP) scale-up relative to HIV incidence in the full period prior to scale-up. Supplemental Table 6 . HIV incidence and unadjusted and adjusted incidence rate ratios comparing HIV incidence among sexually active persons only in each visit interval during combination HIV prevention (CHP) scale-up compared to HIV incidence in the period prior to scale-up. 
